Hepatitis C News and Research

Latest Hepatitis C News and Research

PSI-879 nominated as second development candidate for treating HCV infection

Pharmasset, Inc. announced today the nomination of PSI-352879 (PSI-879) as a second development candidate from two series of purine analogs for the treatment of chronic hepatitis C virus (HCV) infection.

7 Oct 2009

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

PDS Biotechnology Corporation today announced that the company has completed GLP toxicology studies of its lead HPV-cancer product. The studies, which included pharmacokinetic (PK) and adsorption, bio-distribution and excretion (ADE) studies in addition to the evaluation of toxicity, all demonstrated a very safe profile of the drug and PDS Biotech's platform Versamune((TM)) technology.

6 Oct 2009

Hepatitis B Foundation calls for consistent monitoring and referral of HBV infected children

An expert panel of nationally recognized pediatric liver specialists convened by the Hepatitis B Foundation is calling for more consistent monitoring and referral of children chronically infected with the hepatitis B virus (HBV). The panel's recommendations for pediatricians and other primary care practitioners stress the need for routine monitoring of children with chronic HBV infections, and timely consultation with a pediatric liver specialist.

6 Oct 2009

FDA Advisory Committee approves Peginterferon alfa-2b for treating metastatic melanoma

Enzon Pharmaceuticals, Inc. today announced that the FDA Oncologic Drug Advisory Committee voted in favor of recommending approval of PEGINTRON® as a treatment in addition to surgery in patients with metastatic melanoma.

6 Oct 2009

New study to boost immune cells for pathogen resistance and vaccine efficacy in elderly

A new study from the Trudeau Institute in Saranac Lake, New York, demonstrates that immune system cells important for both pathogen resistance and vaccine efficacy live longer in older animals but because of this longevity acquire functional defects. The work may provide new targets for boosting immune system function in older individuals.

6 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009

ArQule completes patient enrollment in ARQ 197 Phase 2 trial for non-small cell lung cancer

ArQule, Inc. (Nasdaq: ARQL) today announced that patient enrollment in a Phase 2 trial with ARQ 197 in non-small cell lung cancer (NSCLC) has been completed.

5 Oct 2009

Preclinical study results of AVL-181 protease inhibitor presented

Avila Therapeutics, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, pan-genotype, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181.

5 Oct 2009

NanoViricides completes a number of financing activities

NanoViricides, Inc. (the "Company"), announced today that it has completed a number of financing activities.

5 Oct 2009

Former President Clinton awards certification for new clean water system

The first chlorination system designed for cities in poor countries is now operating in Port-au-Prince, Haiti, announced Andrew Weiss at the Clinton Global Initiative (CGI) meeting in New York last week. "It's a great success," said Weiss.

5 Oct 2009

Bristol-Myers Squibb to present new data on BARACLUDE and other compounds at the AASLD 2009

New data on four Bristol-Myers Squibb Company (NYSE:BMY) compounds will be presented at the 60th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 30 to November 3.

3 Oct 2009

New technique for blood diagnosis developed

If a person loses a large amount of blood the consequences can be critical. That's why adequate quantities of donated blood have to be kept available in hospitals and blood banks.

3 Oct 2009

Phase 1b clinical trial results of PEG-Interferon lambda to be presented

Bristol-Myers Squibb Company and ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that final results from a Phase 1b clinical trial in patients with hepatitis C (HCV) treated with PEG-Interferon lambda, a new class of interferon, in combination with ribavirin will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting October 30–November 3, 2009, in Boston.

3 Oct 2009

New study underscores lack of appropriate government action to ensure safety of vaccines

A new study in the leading scientific journal NeuroToxicology lends further credence to parents and scientists concerned about an increasingly aggressive childhood vaccine schedule and toxic vaccine components.

2 Oct 2009

China's State Intellectual Property Bureau grants patent for Aoxing Ganbao

Biostar Pharmaceuticals, Inc. ("Biostar" or "the Company"), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced it has received a patent from China's State Intellectual Property Bureau for its Aoxing Ganbao product. The patent number is 551073.

2 Oct 2009

New improved marker-free technique provides faster blood analysis

The analysis takes just a few minutes and the doctor knows straight-away whether there are any pathogens in the blood. An improved marker-free technique provides the basis for faster analysis, whether in a hospital or for mobile blood donations.

1 Oct 2009

Danya International bags contract to operate NPIN for CDC

Danya International, Inc., a communications, research, and technology firm, has been awarded a contract to continue its performance in operating the National Prevention Information Network (NPIN) for the Centers for Disease Control and Prevention (CDC). NPIN provides the latest information, resources, and technology focused on preventing HIV/AIDS, viral hepatitis, STDs, and tuberculosis.

1 Oct 2009

Stanford Hospital invests $3 million in technology for safe patient handling

Swaddled in a cushy green hammock, the patient began her ascent off the bed. While one nurse regulated the speed of the lifting device, two of his colleagues guided the patient toward a bedside chair. Within seconds, she was securely lowered onto a cushion, and ready to begin rehabilitation exercises.

1 Oct 2009

Vertex Pharmaceuticals to receive $155 million in cash from two financial transactions

Vertex Pharmaceuticals Incorporated today announced that it will receive $155 million in cash from two financial transactions. In the first transaction, Vertex will receive approximately $120 million in cash for the issuance of notes repayable no later than October 31, 2012 in the total amount of $155 million.

1 Oct 2009

ABL partners with Evivar Medical to develop and commercialize clinical management tools

Advanced Biological Laboratories S.A (ABL) and Evivar Medical Pty Ltd (Evivar) today announced the completion of agreements to cross-licence their respective intellectual property portfolios, and to form strategic alliances based on the use of their proprietary disease management platforms in HIV and Hepatitis B.

30 Sep 2009

Hepatitis C News and Research

Latest Hepatitis C News and Research

PSI-879 nominated as second development candidate for treating HCV infection

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

Hepatitis B Foundation calls for consistent monitoring and referral of HBV infected children

FDA Advisory Committee approves Peginterferon alfa-2b for treating metastatic melanoma

New study to boost immune cells for pathogen resistance and vaccine efficacy in elderly

Schering-Plough receives FDA recommendation approval for PEGINTRON

ArQule completes patient enrollment in ARQ 197 Phase 2 trial for non-small cell lung cancer

Preclinical study results of AVL-181 protease inhibitor presented

NanoViricides completes a number of financing activities

Former President Clinton awards certification for new clean water system

Bristol-Myers Squibb to present new data on BARACLUDE and other compounds at the AASLD 2009

New technique for blood diagnosis developed

Phase 1b clinical trial results of PEG-Interferon lambda to be presented

New study underscores lack of appropriate government action to ensure safety of vaccines

China's State Intellectual Property Bureau grants patent for Aoxing Ganbao

New improved marker-free technique provides faster blood analysis

Danya International bags contract to operate NPIN for CDC

Stanford Hospital invests $3 million in technology for safe patient handling

Vertex Pharmaceuticals to receive $155 million in cash from two financial transactions

ABL partners with Evivar Medical to develop and commercialize clinical management tools

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hepatitis C News and Research

Latest Hepatitis C News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in